TipRanks
Summit Therapeutics (MX:SMMT)
:SMMT
Mexico Market
SMMT
Summit Therapeutics
RESEARCH TOOLSreports

Summit Therapeutics (SMMT) Income Statement

1 Followers

Summit Therapeutics Income Statement

Last quarter (Q2 2026), Summit Therapeutics's total revenue was £0.00, a decrease of ― from the same quarter last year. In Q2, Summit Therapeutics's net income was £-215.70M. See Summit Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 583.19K$ 1.34M
Gross Profit
$ 0.00$ 0.00$ 0.00$ 583.19K$ 1.34M
Operating Expenses
$ 1.09B$ 180.51M$ 478.23M$ 60.22M$ 65.07M
Depreciation and Amortization
$ 146.00K$ 71.00K$ 155.32K$ 1.04M$ 996.07K
EBITDA
$ -1.08B$ -168.46M$ -69.45M$ -51.58M$ -64.31M
Operating Income
$ -1.09B$ -180.51M$ -478.23M$ -59.63M$ -63.73M
Other Income/Expenses
$ 14.84M$ 3.74M$ -4.14M$ -5.54M$ -1.79M
Pretax Income
$ -1.08B$ -176.77M$ -482.37M$ -65.17M$ -65.52M
Net Income
$ -1.08B$ -176.77M$ -482.37M$ -65.17M$ -65.52M
Per Share Metrics
Basic EPS
$ -1.44$ -0.25$ -0.78$ -0.34$ -0.71
Diluted EPS
$ -1.44$ -0.25$ -0.78$ -0.34$ -0.71
Weighted Average Shares Outstanding
 747.70M 713.92M 619.64M 192.15M 92.24M
Weighted Average Shares Outstanding (Diluted)
 747.70M 718.54M 619.65M 193.34M 92.24M

Summit Therapeutics Earnings and Revenue History